Kevin Hockenberry

Husband, Dad, and #DCISionRT #AidaBreast guy @PreludeDx

[PreludeDx @PreludeDx]

Proud to be featured in the Orange County Business Journal.

The story highlights PreludeDx's growth, AidaBreast®, and our commitment to advancing personalized breast cancer care.

Read more: https://t.co/emRK4Hm9rb

[PreludeDx @PreludeDx]

Big news: @PreludeDx receives FDA Breakthrough Device designation for AidaBREAST®, our assay for early-stage invasive breast cancer. This marks our second, alongside DCISionRT®.
Read more: https://t.co/l3wCDGJytZ

[PreludeDx @PreludeDx]

This video highlights why informed choice is so critical after a breast cancer diagnosis. At PreludeDx, weprovide tools like DCISionRT® and AidaBreast™ that give patients and physicians clarity, confidence, and personalized insights to guide their radiation therapy decisions.

[PreludeDx @PreludeDx]

PreludeDX is on our way to San Francisco for #ASTRO25! Hear the latest from our Red Journal
Clin-Path study, DCISionRT research, and what’s next with AidaBreast. So many ways to connect—we can’t wait to see you! #ASTRO2025

[Kevin Hockenberry @KBHock90]

Join @PreludeDx for a discussion on #genomic and #multiomic testing at #ASTRO25

[PreludeDx @PreludeDx]

Throughout 2025, @HannahStormESPN, award-winning broadcast journalist, director & producer, will share with our audience how precision medicine and #DCISionRT can make a big difference in #breastcancer treatment decisions. Follow along!

[Kevin Hockenberry @KBHock90]

I’m happy to share that I’m returning to an all-star organization as Area Sales Director at @PreludeDx ! New frontiers ahead—Predicting benefit of RT in Early Stage Invasive Breast Cancer! #bcsm #dcis #DCISionRT #esbc #astro #asbrs

[Agendia @Agendia]

🌟 Exciting News Alert! Agendia unveils groundbreaking data from I-SPY 2, unveiling the predictive power of our new Signature ImPrintTN for #TripleNegativeBreastCancer patients' immunotherapy response. Learn more: https://t.co/egPjVNWevo #Agendia #BreastCancer #Immunotherapy

[Kevin Hockenberry @KBHock90]

Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint® - https://t.co/sr0rjkUbvg

[Kevin Hockenberry @KBHock90]

Disparities in Survival Outcomes Revealed With BluePrint and MammaPrint Subtyping in HR+/HER2– Breast Cancer https://t.co/l3YZupTjOX via @onclive

[Kevin Hockenberry @KBHock90]

Agendia, NCI, SWOG to Study Neoadjuvant Immunotherapy, Chemo in High-Risk Breast Cancer Patients | Precision Medicine Online #bcsm https://t.co/U01IDfCacB

[Agendia @Agendia]

Today, we announce our collaboration with the
@theNCI and @SWOG for a new clinical trial, S2206, that will test the effectiveness of neoadjuvant immunotherapy for high-risk HR+ breast cancer patients.https://t.co/cq4b56IDPu

[Kevin Hockenberry @KBHock90]

ASCO® 2023 Insights: "MammaPrint Index as a Predictive Biomarker for Neoadjuvant Chemo Response & Outcome in Patients With HR+/HER2- BC in NBRST" | VuMedi https://t.co/SCVdjY0ZJx via @vumedi

[Carlos Gonzalez @DrMedOnco]

S2206 trial using neoadj durvalumab with standard chemo in Breast cancer ER+HER2 stage II-III mammaprint ultra high patients. The next big step, using genomic firms in decision taking during the neoadj setting.

[Kevin Hockenberry @KBHock90]

Eye opening data when considering that both 21-gene prospective randomized trials show worse outcomes for Black Women than any other race in the RS<25 and RS<11 cohorts. #asco2023 #bcsm #data #dontlumpmein https://t.co/ewTdkL3dTt

[Agendia @Agendia]

See @PeterBeitshMD poster discussion at #ASCO23 on June 4th from 4:30-6:30PM CST Abstract 521, Posterboard 351 https://t.co/eisFqg25lg

[Kevin Hockenberry @KBHock90]

@cwspeers @blake_corum @UMichFootball Just saw you on TV!!—Hey-I know that guy! Go Blue!

[Kevin Hockenberry @KBHock90]

@CarlaFisherMD Excellent paper! Check out recent NBRST paper as well - https://t.co/YmziqyaZ3a

[Agendia @Agendia]

It is not too late to register for our Agendia sponsored EMJ virtual presentation featuring Dr. William Audeh and Dr. Alberto Montero. Find out more and register here: https://t.co/XmOWS1i52s #Agendia #EMJReviews #EMGHealth

[Alabama Football @AlabamaFTBL]

🤟 - Love You Too @TurnerSportsEJ

"Make somebody's life Better."

#BamaFactor #RollTide